GSK offers glimpse at RSV vaccine in at-risk younger adults before ACIP meeting
GSK is presenting its case for broader use of its RSV vaccine with new data from a pair of studies in younger adults with underlying …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
